Metabolic reprogramming and two-compartment tumor metabolism

Opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells

Barbara Chiavarina, Ubaldo E. Martinez-Outschoorn, Diana Whitaker-Menezes, Anthony Howell, Herbert B. Tanowitz, Richard G. Pestell, Federica Sotgia, Michael P. Lisanti

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Hypoxia-inducible factor (HIF) 1α and 2α are transcription factors responsible for the cellular response to hypoxia. The functional roles of HIF1α and HIF2α in cancer are distinct and vary among different tumor types. The aim of this study was to evaluate the compartment-specific role(s) of HIF1α and HIF2α in breast cancer. To this end, immortalized human fibroblasts and MDA-MB-231 breast cancer cells carrying constitutively active HIF1α or HIF2α mutants were analyzed with respect to their metabolic function(s) and ability to promote tumor growth in an in vivo setting. We observed that activation of HIF1α , but not HIF2α, in stromal cells promotes a shift toward aerobic glycolysis, with increased L-lactate production and a loss of mitochondrial activity. In a xenograft model, HIF1α-activated fibroblasts promoted the tumor growth of co-injected MDA-MB-231 cells without an increase in angiogenesis. Conversely, HIF2α-activated stromal cells did not favor tumor growth and behaved as the empty vector controls. Similarly, activation of HIF1α, but not HIF2α, in MDA-MB-231 cells promoted a shift toward aerobic glycolysis, with increased glucose uptake and L-lactate production. In contrast, HIF2α activation in cancer cells increased the expression of EGFR, Ras and cyclin D1, which are known markers of tumor growth and cell cycle progression. In a xenograft model, HIF1α activation in MDA-MB-231 cells acted as a tumor suppressor, resulting in an almost 2-fold reduction in tumor mass and volume. Interestingly, HIF2α activation in MDA-MB-231 cells induced a significant ∼2-fold-increase in tumor mass and volume. Analysis of mitochondrial activity in these tumor xenografts using COX (cytochrome C oxidase) staining demonstrated elevated mitochondrial oxidative metabolism (OXPHOS) in HIF2α-tumors. We conclude that the role(s) of HIF1α and HIF2α in tumorigenesis are compartment-specific. HIF1α acts as a tumor promoter in stromal cells but as a tumor suppressor in cancer cells. Conversely, HIF2α is a tumor promoter in cancer cells. Mechanistically, HIF1α-driven aerobic glycolysis in stromal cells supports cancer cell growth via the paracrine production of nutrients (such as L-lactate) that can "feed" cancer cells. However, HIF1α-driven aerobic glycolysis in cancer cells inhibits tumor growth. Finally, HIF2α activation in cancer cells induces the expression of known pro-oncogenic molecules and promotes the mitochondrial activity of cancer cells.

Original languageEnglish (US)
Pages (from-to)3280-3289
Number of pages10
JournalCell Cycle
Volume11
Issue number17
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Breast Neoplasms
Neoplasms
Glycolysis
Stromal Cells
Growth
Heterografts
Cancer-Associated Fibroblasts
Lactic Acid
Tumor Burden
Carcinogens
Fibroblasts
Hypoxia-Inducible Factor 1
Cyclin D1
Electron Transport Complex IV
Tumor Biomarkers
Cell Cycle
Carcinogenesis
Transcription Factors
Staining and Labeling
Glucose

Keywords

  • Aerobic glycolysis
  • Cancer-associated fibroblasts
  • Caveolin-1
  • HIF-1α
  • HIF-2α
  • Hypoxia-inducible factor
  • Metabolic coupling
  • Mitochondrial metabolism
  • OXPHOS
  • Tumor stroma

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology

Cite this

Chiavarina, B., Martinez-Outschoorn, U. E., Whitaker-Menezes, D., Howell, A., Tanowitz, H. B., Pestell, R. G., ... Lisanti, M. P. (2012). Metabolic reprogramming and two-compartment tumor metabolism: Opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells. Cell Cycle, 11(17), 3280-3289. https://doi.org/10.4161/cc.21643

Metabolic reprogramming and two-compartment tumor metabolism : Opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells. / Chiavarina, Barbara; Martinez-Outschoorn, Ubaldo E.; Whitaker-Menezes, Diana; Howell, Anthony; Tanowitz, Herbert B.; Pestell, Richard G.; Sotgia, Federica; Lisanti, Michael P.

In: Cell Cycle, Vol. 11, No. 17, 01.09.2012, p. 3280-3289.

Research output: Contribution to journalArticle

Chiavarina, B, Martinez-Outschoorn, UE, Whitaker-Menezes, D, Howell, A, Tanowitz, HB, Pestell, RG, Sotgia, F & Lisanti, MP 2012, 'Metabolic reprogramming and two-compartment tumor metabolism: Opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells', Cell Cycle, vol. 11, no. 17, pp. 3280-3289. https://doi.org/10.4161/cc.21643
Chiavarina, Barbara ; Martinez-Outschoorn, Ubaldo E. ; Whitaker-Menezes, Diana ; Howell, Anthony ; Tanowitz, Herbert B. ; Pestell, Richard G. ; Sotgia, Federica ; Lisanti, Michael P. / Metabolic reprogramming and two-compartment tumor metabolism : Opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells. In: Cell Cycle. 2012 ; Vol. 11, No. 17. pp. 3280-3289.
@article{072fba7564ae4f9d918bbcb551583c98,
title = "Metabolic reprogramming and two-compartment tumor metabolism: Opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells",
abstract = "Hypoxia-inducible factor (HIF) 1α and 2α are transcription factors responsible for the cellular response to hypoxia. The functional roles of HIF1α and HIF2α in cancer are distinct and vary among different tumor types. The aim of this study was to evaluate the compartment-specific role(s) of HIF1α and HIF2α in breast cancer. To this end, immortalized human fibroblasts and MDA-MB-231 breast cancer cells carrying constitutively active HIF1α or HIF2α mutants were analyzed with respect to their metabolic function(s) and ability to promote tumor growth in an in vivo setting. We observed that activation of HIF1α , but not HIF2α, in stromal cells promotes a shift toward aerobic glycolysis, with increased L-lactate production and a loss of mitochondrial activity. In a xenograft model, HIF1α-activated fibroblasts promoted the tumor growth of co-injected MDA-MB-231 cells without an increase in angiogenesis. Conversely, HIF2α-activated stromal cells did not favor tumor growth and behaved as the empty vector controls. Similarly, activation of HIF1α, but not HIF2α, in MDA-MB-231 cells promoted a shift toward aerobic glycolysis, with increased glucose uptake and L-lactate production. In contrast, HIF2α activation in cancer cells increased the expression of EGFR, Ras and cyclin D1, which are known markers of tumor growth and cell cycle progression. In a xenograft model, HIF1α activation in MDA-MB-231 cells acted as a tumor suppressor, resulting in an almost 2-fold reduction in tumor mass and volume. Interestingly, HIF2α activation in MDA-MB-231 cells induced a significant ∼2-fold-increase in tumor mass and volume. Analysis of mitochondrial activity in these tumor xenografts using COX (cytochrome C oxidase) staining demonstrated elevated mitochondrial oxidative metabolism (OXPHOS) in HIF2α-tumors. We conclude that the role(s) of HIF1α and HIF2α in tumorigenesis are compartment-specific. HIF1α acts as a tumor promoter in stromal cells but as a tumor suppressor in cancer cells. Conversely, HIF2α is a tumor promoter in cancer cells. Mechanistically, HIF1α-driven aerobic glycolysis in stromal cells supports cancer cell growth via the paracrine production of nutrients (such as L-lactate) that can {"}feed{"} cancer cells. However, HIF1α-driven aerobic glycolysis in cancer cells inhibits tumor growth. Finally, HIF2α activation in cancer cells induces the expression of known pro-oncogenic molecules and promotes the mitochondrial activity of cancer cells.",
keywords = "Aerobic glycolysis, Cancer-associated fibroblasts, Caveolin-1, HIF-1α, HIF-2α, Hypoxia-inducible factor, Metabolic coupling, Mitochondrial metabolism, OXPHOS, Tumor stroma",
author = "Barbara Chiavarina and Martinez-Outschoorn, {Ubaldo E.} and Diana Whitaker-Menezes and Anthony Howell and Tanowitz, {Herbert B.} and Pestell, {Richard G.} and Federica Sotgia and Lisanti, {Michael P.}",
year = "2012",
month = "9",
day = "1",
doi = "10.4161/cc.21643",
language = "English (US)",
volume = "11",
pages = "3280--3289",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "17",

}

TY - JOUR

T1 - Metabolic reprogramming and two-compartment tumor metabolism

T2 - Opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells

AU - Chiavarina, Barbara

AU - Martinez-Outschoorn, Ubaldo E.

AU - Whitaker-Menezes, Diana

AU - Howell, Anthony

AU - Tanowitz, Herbert B.

AU - Pestell, Richard G.

AU - Sotgia, Federica

AU - Lisanti, Michael P.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Hypoxia-inducible factor (HIF) 1α and 2α are transcription factors responsible for the cellular response to hypoxia. The functional roles of HIF1α and HIF2α in cancer are distinct and vary among different tumor types. The aim of this study was to evaluate the compartment-specific role(s) of HIF1α and HIF2α in breast cancer. To this end, immortalized human fibroblasts and MDA-MB-231 breast cancer cells carrying constitutively active HIF1α or HIF2α mutants were analyzed with respect to their metabolic function(s) and ability to promote tumor growth in an in vivo setting. We observed that activation of HIF1α , but not HIF2α, in stromal cells promotes a shift toward aerobic glycolysis, with increased L-lactate production and a loss of mitochondrial activity. In a xenograft model, HIF1α-activated fibroblasts promoted the tumor growth of co-injected MDA-MB-231 cells without an increase in angiogenesis. Conversely, HIF2α-activated stromal cells did not favor tumor growth and behaved as the empty vector controls. Similarly, activation of HIF1α, but not HIF2α, in MDA-MB-231 cells promoted a shift toward aerobic glycolysis, with increased glucose uptake and L-lactate production. In contrast, HIF2α activation in cancer cells increased the expression of EGFR, Ras and cyclin D1, which are known markers of tumor growth and cell cycle progression. In a xenograft model, HIF1α activation in MDA-MB-231 cells acted as a tumor suppressor, resulting in an almost 2-fold reduction in tumor mass and volume. Interestingly, HIF2α activation in MDA-MB-231 cells induced a significant ∼2-fold-increase in tumor mass and volume. Analysis of mitochondrial activity in these tumor xenografts using COX (cytochrome C oxidase) staining demonstrated elevated mitochondrial oxidative metabolism (OXPHOS) in HIF2α-tumors. We conclude that the role(s) of HIF1α and HIF2α in tumorigenesis are compartment-specific. HIF1α acts as a tumor promoter in stromal cells but as a tumor suppressor in cancer cells. Conversely, HIF2α is a tumor promoter in cancer cells. Mechanistically, HIF1α-driven aerobic glycolysis in stromal cells supports cancer cell growth via the paracrine production of nutrients (such as L-lactate) that can "feed" cancer cells. However, HIF1α-driven aerobic glycolysis in cancer cells inhibits tumor growth. Finally, HIF2α activation in cancer cells induces the expression of known pro-oncogenic molecules and promotes the mitochondrial activity of cancer cells.

AB - Hypoxia-inducible factor (HIF) 1α and 2α are transcription factors responsible for the cellular response to hypoxia. The functional roles of HIF1α and HIF2α in cancer are distinct and vary among different tumor types. The aim of this study was to evaluate the compartment-specific role(s) of HIF1α and HIF2α in breast cancer. To this end, immortalized human fibroblasts and MDA-MB-231 breast cancer cells carrying constitutively active HIF1α or HIF2α mutants were analyzed with respect to their metabolic function(s) and ability to promote tumor growth in an in vivo setting. We observed that activation of HIF1α , but not HIF2α, in stromal cells promotes a shift toward aerobic glycolysis, with increased L-lactate production and a loss of mitochondrial activity. In a xenograft model, HIF1α-activated fibroblasts promoted the tumor growth of co-injected MDA-MB-231 cells without an increase in angiogenesis. Conversely, HIF2α-activated stromal cells did not favor tumor growth and behaved as the empty vector controls. Similarly, activation of HIF1α, but not HIF2α, in MDA-MB-231 cells promoted a shift toward aerobic glycolysis, with increased glucose uptake and L-lactate production. In contrast, HIF2α activation in cancer cells increased the expression of EGFR, Ras and cyclin D1, which are known markers of tumor growth and cell cycle progression. In a xenograft model, HIF1α activation in MDA-MB-231 cells acted as a tumor suppressor, resulting in an almost 2-fold reduction in tumor mass and volume. Interestingly, HIF2α activation in MDA-MB-231 cells induced a significant ∼2-fold-increase in tumor mass and volume. Analysis of mitochondrial activity in these tumor xenografts using COX (cytochrome C oxidase) staining demonstrated elevated mitochondrial oxidative metabolism (OXPHOS) in HIF2α-tumors. We conclude that the role(s) of HIF1α and HIF2α in tumorigenesis are compartment-specific. HIF1α acts as a tumor promoter in stromal cells but as a tumor suppressor in cancer cells. Conversely, HIF2α is a tumor promoter in cancer cells. Mechanistically, HIF1α-driven aerobic glycolysis in stromal cells supports cancer cell growth via the paracrine production of nutrients (such as L-lactate) that can "feed" cancer cells. However, HIF1α-driven aerobic glycolysis in cancer cells inhibits tumor growth. Finally, HIF2α activation in cancer cells induces the expression of known pro-oncogenic molecules and promotes the mitochondrial activity of cancer cells.

KW - Aerobic glycolysis

KW - Cancer-associated fibroblasts

KW - Caveolin-1

KW - HIF-1α

KW - HIF-2α

KW - Hypoxia-inducible factor

KW - Metabolic coupling

KW - Mitochondrial metabolism

KW - OXPHOS

KW - Tumor stroma

UR - http://www.scopus.com/inward/record.url?scp=84866294574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866294574&partnerID=8YFLogxK

U2 - 10.4161/cc.21643

DO - 10.4161/cc.21643

M3 - Article

VL - 11

SP - 3280

EP - 3289

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 17

ER -